セッション詳細
[WS(O)26]Systemic Immune Diseases
2024年12月5日(木) 12:50 〜 14:11
Room E
Organizers: Hirofumi Shoda (Tokyo Medical University), Yohei Kirino (Yokohama City University Graduate School of Medicine)
[WS26-01-O/P]Multimodal single-cell analysis revealed B cell receptor dynamic change in systemic lupus erythematosus
○Toshiyuki Shiki Ushijima1, Hiroyuki Teruya1, Manaka Goto1, Hideyuki Takahashi1, Takahiro Itamiya1,2, Haruka Tsuchiya1, Hirofumi Shoda1, Tomohisa Okamura1,2, Keishi Fujio1 (1.Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 2.Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo)
[WS26-03-O/P]The B cell inhibitory receptor CD72 is a novel C1q receptor that prevents development of SLE by inhibiting B cell response to apoptotic cells.
○Hashadi Nadeesha Walakulu Gamage1,2,3, Chizuru Akatsu2, Nobutaka Numoto1, Takahiro Tsuneshige1,2,3, Masatake Asano3, Nobutoshi Ito1, Takeshi Tsubata1,2,3 (1.Department of Structural Biology, Medical Research Institute, Tokyo Medical and Dental University, 2.Department of Immunology, Medical Research Institute, Tokyo Medical and Dental University, 3.Department of Pathology, Nihon University School of Dentistry)
[WS26-04-O/P]New quantitative and qualitative analytical framework of scRNAseq data reveals the pathophysiology of systemic lupus erythematosus
○Masahiro Nakano1, Michihiro Kono1,2, Hiroaki Hatano1, Kenichiro Asahara1, Takahiro Nishino1, Haruka Takahashi1,2, Bunki Natsumoto1, Kazuyoshi Ishigaki1,2,3 (1.Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, 2.Department of Microbiology and Immunology, Keio University School of Medicine, 3.Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q))
[WS26-06-O/P]Development of the anti-human TLR7 monoclonal antibody for therapeutic intervention in systemic lupus erythematosus
○Ryutaro Fukui1, Yusuke Murakami2,1, Atsuo Kanno1, Yuji Motoi1, Atsushi Manno4, Tomohiro Honda5, Shinnosuke Yamada5, Jun Ishiguro6, Kensuke Nakamura7, Giorgio Senaldi8, Toshiyuki Shimizu3, Kensuke Miyake1 (1.The Institute of Medical Science, The University of Tokyo, 2.Department of Pharmaceutical Sciences & Research Institute of Pharmaceutical Sciences, Musashino University, 3.Graduate School of Pharmaceutical Sciences, The University of Tokyo, 4.Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., 5.Translational Science Department II, Daiichi Sankyo Co., Ltd., 6.Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., 7.Modality Research Laboratories II, Daiichi Sankyo Co., Ltd., 8.Clinical development, Daiichi Sankyo, Inc.)
[WS26-14-O/P]Salivary gland fibroblasts drive autoimmune pathology via the interaction with CD4+ T cells in Sjögren’s syndrome
○Kunihiro Otsuka1,2, Hiroyuki Kondo1, Shin-Ichi Tsukumo1, Naozumi Ishimaru3, Koji Yasutomo1 (1.Department of Immunology and Parasitology, Graduate School of Medicine, Tokushima University, 2.Department of Oral Molecular Pathology, Graduate School of Dentistry, Tokushima University, 3.Department of Oral Pathology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences)
[WS26-17-O/P]Anti-integrin αvβ6 antibody in Takayasu arteritis with or without ulcerative colitis
○Yuki Ishikawa1, Hiroyuki Yoshida2,3, Hajime Yoshifuji4, Koichiro Ohmura4,5, Tomoki Origuchi6, Tomonori Ishii7, Tsuneyo Mimori4,8, Akio Morinobu4, Masahiro Shiokawa2, Chikashi Terao1,9,10 (1.Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, 2.Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 3.Kansai Electric Power Hospital, 4.Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 5.Department of Rheumatology, Kobe City Medical Center General Hospital, 6.Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 7.Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, 8.Takeda Clinic for Rheumatic Diseases, 9.Clinical Research Center, Shizuoka General Hospital, 10.School of Pharmaceutical Sciences, University of Shizuoka, The Department of Applied Genetics)
[WS26-18-O/P]Unravelling the gene regulatory networks driving the polygenetic risk of human complex diseases
○Haruka Takahashi1,2, Hiroaki Hatano2, Masahiro Nakano2, Yumi Tsuchida3, Shuji Sumitomo3, Akari Suzuki4, Yuta Kochi5, Keishi Fujio3, Kazuhiko Yamamoto4, Kazuyoshi Ishigaki1,2,6 (1.Department of Microbiology and Immunology, Keio University School of Medicine, 2.Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, 3.Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 4.Laboratory for Autoimmune Diseases, Riken Center for Integrative Medical Sciences, 5.Department of Genomic Function and Diversity, Division of Biological Data Science, Medical Research Institute, Tokyo Medical and Dental University, 6.Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q))
[WS26-25-O/P]Novel transcriptomic evidence for a shared immunological signature-based treatment of Adult-onset Still's disease and other autoinflammatory diseases
○Ikuo Takazawa1, Haruka Tsuchiya1, Takahiro Itamiya1,2, Harumi Shirai1, Yumi Tsuchida1, Yasuo Nagafuchi1,2, Hirofumi Shoda1, Tomohisa Okamura1,2, Keishi Fujio1 (1.Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 2.Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo)
[WS26-26-O/P]Isoliquiritigenin inhibits activation of NLRP3 inflammasome with CAPS mutations by suppressing caspase-1 activation and mutant NLRP3 aggregation
○Koudai Kani1, Hiroe Honda2, Kiyoshi Takatsu2, Yoshinori Nagai1 (1.Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 2.Toyama Prefectural Institute for Pharmaceutical Research)